Up to 40% off Clearance!* New items added
AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia
AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia
AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia
AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia
AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia
AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

1/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

2/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

3/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

4/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

5/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

6/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

7/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

8/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

9/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

10/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

11/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

12/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

13/13

AstraZeneca Buys Remaining China Rights To GPC3 Armored CAR-T Therapy From AbelZeta Pharma For $630 M Australia

$31

Collect 1 Flybuys point per $1 spent
31 pts

Buy now pay later


Item code: 670789

Reviews

Rating Snapshot

Select a row below to filter reviews.
33 reviews with 5 stars.
2 reviews with 4 stars.
4 reviews with 3 stars.
2 reviews with 2 stars.
2 reviews with 1 stars.

Overall Rating

4.8